<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38539680</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-3425</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Brain sciences</Title><ISOAbbreviation>Brain Sci</ISOAbbreviation></Journal><ArticleTitle>Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">293</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/brainsci14030293</ELocationID><Abstract><AbstractText>Neurological involvement following coronavirus disease 19 (COVID-19) is thought to have a neuroinflammatory etiology. Co-ultraPEALut (an anti-inflammatory molecule) and luteolin (an anti-oxidant) have shown promising results as neuroinflammation antagonists. The aim of this study was to describe cognitive impairment in patients with post-COVID-19 treated with co-ultraPEALut. The Montreal Cognitive Assessment (MoCA), the Prospective-Retrospective Memory Questionnaire (PRMQ), the Fatigue Severity Scale (FSS), and a subjective assessment were administered at baseline and after 10 months. Patients treated with co-ultraPEALut were retrospectively compared with controls. Twenty-six patients treated with co-ultraPEALut showed a significant improvement in PRMQ (T0: 51.94 &#xb1; 10.55, T1: 39.67 &#xb1; 13.02, <i>p</i> &lt; 0.00001) and MoCA raw score (T0: 25.76 &#xb1; 2.3, T1: 27.2 &#xb1; 2, <i>p</i> 0.0260); the MoCA-adjusted score and the FSS questionnaires also showed an improvement, even though it was not statistically significant; and 80.77% of patients reported a subjective improvement. In the control subjects (<i>n</i> = 15), the improvement was not as pronounced (PRMQ T0: 45.77 &#xb1; 13.47, T1: 42.33 &#xb1; 16.86, <i>p</i> 0.2051; FSS T0: 4.95 &#xb1; 1.57, T1: 4.06 &#xb1; 1.47, <i>p</i> 0.1352). Patients treated with co-ultraPEALut and corticosteroids were not statistically different from those treated with co-ultraPEALut alone. Neuro-post-COVID-19 patients treated with co-ultraPEALut scored better than controls in MoCA and PRMQ questionnaires after 10 months: this may support the importance of neuroinflammation modulation for neuro-long-COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cenacchi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste-ASUGI, University of Trieste, Strada di Fiume, 447, 34149 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furlanis</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste-ASUGI, University of Trieste, Strada di Fiume, 447, 34149 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menichelli</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuropsychological Service, Clinical Unit of Rehabilitation, University Hospital and Health Services of Trieste, ASUGI, 34125 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunardelli</LastName><ForeName>Alberta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuropsychological Service, Clinical Unit of Rehabilitation, University Hospital and Health Services of Trieste, ASUGI, 34125 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pesavento</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neuropsychological Service, Clinical Unit of Rehabilitation, University Hospital and Health Services of Trieste, ASUGI, 34125 Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manganotti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste-ASUGI, University of Trieste, Strada di Fiume, 447, 34149 Trieste, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Sci</MedlineTA><NlmUniqueID>101598646</NlmUniqueID><ISSNLinking>2076-3425</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">co-ultraPEALut</Keyword><Keyword MajorTopicYN="N">cognitive impairment</Keyword><Keyword MajorTopicYN="N">long-COVID-19</Keyword><Keyword MajorTopicYN="N">neuro-long-COVID-19</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38539680</ArticleId><ArticleId IdType="pmc">PMC10968982</ArticleId><ArticleId IdType="doi">10.3390/brainsci14030293</ArticleId><ArticleId IdType="pii">brainsci14030293</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ceban F., Ling S., Lui L.M.W., Lee Y., Gill H., Teopiz K.M., Rodrigues N.B., Subramaniapillai M., Di Vincenzo J.D., Cao B., et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Overview|COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19|Guidance|NICE. 2020.  [(accessed on 26 May 2023)].  Available online:  https://www.nice.org.uk/guidance/ng188.</Citation></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long COVID&#x2014;Mechanisms, Risk Factors, and Management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelutti M., Furlanis G., Stella A.B., Bellavita G., Frezza N., Torresin G., Aj&#x10d;evi&#x107; M., Manganotti P. Sex-dependent characteristics of Neuro-Long-COVID: Data from a dedicated neurology ambulatory service. J. Neurol. Sci. 2022;441:120355. doi: 10.1016/j.jns.2022.120355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120355</ArticleId><ArticleId IdType="pmc">PMC9328838</ArticleId><ArticleId IdType="pubmed">35994869</ArticleId></ArticleIdList></Reference><Reference><Citation>Teodoro T., Chen J., Gelauff J., Edwards M.J. Functional neurological disorder in people with long COVID: A systematic review. Eur. J. Neurol. 2023;30:1505&#x2013;1514. doi: 10.1111/ene.15721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15721</ArticleId><ArticleId IdType="pubmed">36719069</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Feltz-Cornelis C.M., Moriarty A.S., Strain W.D. Neurological Dysfunction in Long COVID Should Not Be Labelled as Functional Neurological Disorder. Viruses. 2023;15:783. doi: 10.3390/v15030783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030783</ArticleId><ArticleId IdType="pmc">PMC10059786</ArticleId><ArticleId IdType="pubmed">36992491</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolato B., Carvalho A.F., Soczynska J.K., Perini G.I., McIntyre R.S. The Involvement of TNF-&#x3b1; in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Curr. Neuropharmacol. 2015;13:558&#x2013;576. doi: 10.2174/1570159X13666150630171433.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X13666150630171433</ArticleId><ArticleId IdType="pmc">PMC4761629</ArticleId><ArticleId IdType="pubmed">26467407</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulla R., Rossi L., Furlanis G., Agostinis C., Toffoli M., Balduit A., Mangogna A., Liccari M., Morosini G., Kishore U., et al. A likely association between low mannan-binding lectin level and brain fog onset in long COVID patients. Front. Immunol. 2023;14:1191083. doi: 10.3389/fimmu.2023.1191083.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1191083</ArticleId><ArticleId IdType="pmc">PMC10312368</ArticleId><ArticleId IdType="pubmed">37398656</ArticleId></ArticleIdList></Reference><Reference><Citation>Caltagirone C., Cisari C., Schievano C., Di Paola R., Cordaro M., Bruschetta G., Esposito E., Cuzzocrea S., Stroke Study Group Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: From Rodent to Man. Transl. Stroke Res. 2016;7:54&#x2013;69. doi: 10.1007/s12975-015-0440-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12975-015-0440-8</ArticleId><ArticleId IdType="pmc">PMC4720704</ArticleId><ArticleId IdType="pubmed">26706245</ArticleId></ArticleIdList></Reference><Reference><Citation>Campolo M., Crupi R., Cordaro M., Cardali S.M., Ardizzone A., Casili G., Scuderi S.A., Siracusa R., Esposito E., Conti A., et al. Co-Ultra PEALut Enhances Endogenous Repair Response Following Moderate Traumatic Brain Injury. Int. J. Mol. Sci. 2021;22:8717. doi: 10.3390/ijms22168717.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168717</ArticleId><ArticleId IdType="pmc">PMC8395716</ArticleId><ArticleId IdType="pubmed">34445417</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusa R., Impellizzeri D., Cordaro M., Crupi R., Esposito E., Petrosino S., Cuzzocrea S. Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia. Front. Neurol. 2017;8:233. doi: 10.3389/fneur.2017.00233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00233</ArticleId><ArticleId IdType="pmc">PMC5460147</ArticleId><ArticleId IdType="pubmed">28634464</ArticleId></ArticleIdList></Reference><Reference><Citation>Capra A.P., Ardizzone A., Crupi L., Calapai F., Campolo M., Cuzzocrea S., Esposito E. Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies. Biomedicines. 2023;11:2189. doi: 10.3390/biomedicines11082189.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11082189</ArticleId><ArticleId IdType="pmc">PMC10452638</ArticleId><ArticleId IdType="pubmed">37626685</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., D&#x2019;ascanio L., Vaira L.A., Cantone E., De Luca P., Cingolani C., Motta G., De Riu G., Vitelli F., Spriano G., et al. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial. Curr. Neuropharmacol. 2022;20:2001&#x2013;2012. doi: 10.2174/1570159X20666220420113513.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X20666220420113513</ArticleId><ArticleId IdType="pmc">PMC9886808</ArticleId><ArticleId IdType="pubmed">35450527</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P., Camaioni A., Marra P., Salzano G., Carriere G., Ricciardi L., Pucci R., Montemurro N., Brenner M.J., Di Stadio A. Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells. 2022;11:2552. doi: 10.3390/cells11162552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11162552</ArticleId><ArticleId IdType="pmc">PMC9406356</ArticleId><ArticleId IdType="pubmed">36010630</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloe L., Leon A., Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions. 1993;39:C145&#x2013;C147. doi: 10.1007/BF01972748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01972748</ArticleId><ArticleId IdType="pubmed">7505999</ArticleId></ArticleIdList></Reference><Reference><Citation>Impellizzeri D., Bruschetta G., Cordaro M., Crupi R., Siracusa R., Esposito E., Cuzzocrea S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J. Neuroinflamm. 2014;11:136. doi: 10.1186/s12974-014-0136-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0136-0</ArticleId><ArticleId IdType="pmc">PMC4171547</ArticleId><ArticleId IdType="pubmed">25164769</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Cordaro M., Verde R., Schiano Moriello A., Marcolongo G., Schievano C., Siracusa R., Piscitelli F., Peritore A.F., Crupi R., et al. Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Front. Pharmacol. 2018;9:249. doi: 10.3389/fphar.2018.00249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00249</ArticleId><ArticleId IdType="pmc">PMC5870042</ArticleId><ArticleId IdType="pubmed">29615912</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paola R., Fusco R., Gugliandolo E., Crupi R., Evangelista M., Granese R., Cuzzocrea S. Co-micronized Palmitoylethanolamide/Polydatin Treatment Causes Endometriotic Lesion Regression in a Rodent Model of Surgically Induced Endometriosis. Front. Pharmacol. 2016;7:382. doi: 10.3389/fphar.2016.00382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2016.00382</ArticleId><ArticleId IdType="pmc">PMC5063853</ArticleId><ArticleId IdType="pubmed">27790149</ArticleId></ArticleIdList></Reference><Reference><Citation>Peritore A.F., Siracusa R., Crupi R., Cuzzocrea S. Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets. Nutrients. 2019;11:2175. doi: 10.3390/nu11092175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11092175</ArticleId><ArticleId IdType="pmc">PMC6769461</ArticleId><ArticleId IdType="pubmed">31514292</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br. J. Pharmacol. 2017;174:1349&#x2013;1365. doi: 10.1111/bph.13580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13580</ArticleId><ArticleId IdType="pmc">PMC5429331</ArticleId><ArticleId IdType="pubmed">27539936</ArticleId></ArticleIdList></Reference><Reference><Citation>Xagorari A., Papapetropoulos A., Mauromatis A., Economou M., Fotsis T., Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J. Pharmacol. Exp. Ther. 2001;296:181&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11123379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.C., Chow M.P., Huang W.C., Lin Y.C., Chang Y.J. Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB: Structure-activity relationships&#x2019;. Mol. Pharmacol. 2004;66:683&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumazawa Y., Kawaguchi K., Takimoto H. Immunomodulating Effects of Flavonoids on Acute and Chronic Inflammatory Responses Caused by Tumor Necrosis Factor &#x3b1;. Curr. Pharm. Des. 2006;12:4271&#x2013;4279. doi: 10.2174/138161206778743565.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161206778743565</ArticleId><ArticleId IdType="pubmed">17100629</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelinger G., Merfort I., Schempp C.M. Anti-Oxidant, Anti-Inflammatory and Anti-Allergic Activities of Luteolin. Planta Medica. 2008;74:1667&#x2013;1677. doi: 10.1055/s-0028-1088314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0028-1088314</ArticleId><ArticleId IdType="pubmed">18937165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama I. Brain Leukocytes as the Potential Therapeutic Target for Post-COVID-19 Brain Fog. Neurochem. Res. 2023;48:2345&#x2013;2349. doi: 10.1007/s11064-023-03912-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-023-03912-0</ArticleId><ArticleId IdType="pmc">PMC10034247</ArticleId><ArticleId IdType="pubmed">36952147</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello E.N., Gramegna C., Esposito A., Gazzaniga V., Zago S., Difonzo T., Maddaluno O., Appollonio I., Bolognini N. The Montreal Cognitive Assessment (MoCA): Updated norms and psychometric insights into adaptive testing from healthy individuals in Northern Italy. Aging Clin. Exp. Res. 2022;34:375&#x2013;382. doi: 10.1007/s40520-021-01943-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-021-01943-7</ArticleId><ArticleId IdType="pmc">PMC8847194</ArticleId><ArticleId IdType="pubmed">34313961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine Z.S., Phillips N.A., B&#xe9;dirian V., Charbonneau S., Whitehead V., Collin I., Cummings J.L., Chertkow H. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J. Am. Geriatr. Soc. 2005;53:695&#x2013;699. doi: 10.1111/j.1532-5415.2005.53221.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello E.N., Fiabane E., Manera M.R., Radici A., Grossi F., Ottonello M., Pain D., Pistarini C. Screening for cognitive sequelae of SARS-CoV-2 infection: A comparison between the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) Neurol. Sci. 2022;43:81&#x2013;84. doi: 10.1007/s10072-021-05630-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05630-3</ArticleId><ArticleId IdType="pmc">PMC8526352</ArticleId><ArticleId IdType="pubmed">34668124</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The Fatigue Severity Scale: Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus. Arch. Neurol. 1989;46:1121&#x2013;1123. doi: 10.1001/archneur.1989.00520460115022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1989.00520460115022</ArticleId><ArticleId IdType="pubmed">2803071</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton H.A., Miller W.C., Townson A.F. Measuring Fatigue in Persons With Spinal Cord Injury. Arch. Phys. Med. Rehabil. 2008;89:538&#x2013;542. doi: 10.1016/j.apmr.2007.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmr.2007.11.009</ArticleId><ArticleId IdType="pmc">PMC3595300</ArticleId><ArticleId IdType="pubmed">18295634</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith G., Del Sala S., Logie R.H., Maylor E.A. Prospective and retrospective memory in normal ageing and dementia: A questionnaire study. Memory. 2000;8:311&#x2013;321. doi: 10.1080/09658210050117735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09658210050117735</ArticleId><ArticleId IdType="pubmed">11045239</ArticleId></ArticleIdList></Reference><Reference><Citation>e Silva N.M.L., Barros-Arag&#xe3;o F.G., De Felice F.G., Ferreira S.T. Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology. 2022;209:109023. doi: 10.1016/j.neuropharm.2022.109023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2022.109023</ArticleId><ArticleId IdType="pmc">PMC8894741</ArticleId><ArticleId IdType="pubmed">35257690</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R., Hert L., De Marchis G.M., Twerenbold R., Kappos L., Naegelin Y., Kuster G.M., Benkert P., Jost J., Msc A.M.M., et al. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Ann. Neurol. 2021;89:610&#x2013;616. doi: 10.1002/ana.26004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26004</ArticleId><ArticleId IdType="pubmed">33377539</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueiredo C.P., Barros-Arag&#xe3;o F.G.Q., Neris R.L.S., Frost P.S., Soares C., Souza I.N.O., Zeidler J.D., Zamberlan D.C., de Sousa V.L., Souza A.S., et al. Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice. Nat. Commun. 2019;10:3890. doi: 10.1038/s41467-019-11866-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11866-7</ArticleId><ArticleId IdType="pmc">PMC6728367</ArticleId><ArticleId IdType="pubmed">31488835</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton M.D., Johnson R.W. Interleukin-6 trans-signaling in the senescent mouse brain is involved in infection-related deficits in contextual fear conditioning. Brain Behav. Immun. 2012;26:732&#x2013;738. doi: 10.1016/j.bbi.2011.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2011.10.008</ArticleId><ArticleId IdType="pmc">PMC3699311</ArticleId><ArticleId IdType="pubmed">22062497</ArticleId></ArticleIdList></Reference><Reference><Citation>Stella A.B., Furlanis G., Frezza N.A., Valentinotti R., Ajcevic M., Manganotti P. Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms: A prospective multidomain observational study. J. Neurol. 2022;269:587&#x2013;596. doi: 10.1007/s00415-021-10735-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10735-y</ArticleId><ArticleId IdType="pmc">PMC8359764</ArticleId><ArticleId IdType="pubmed">34386903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza M.G., Palladini M., De Lorenzo R., Magnaghi C., Poletti S., Furlan R., Ciceri F., Rovere-Querini P., Benedetti F. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav. Immun. 2021;94:138&#x2013;147. doi: 10.1016/j.bbi.2021.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.02.021</ArticleId><ArticleId IdType="pmc">PMC7903920</ArticleId><ArticleId IdType="pubmed">33639239</ArticleId></ArticleIdList></Reference><Reference><Citation>Fudim M., Qadri Y.J., Ghadimi K., MacLeod D.B., Molinger J., Piccini J.P., Whittle J., Wischmeyer P.E., Patel M.R., Ulloa L. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19. J. Cardiovasc. Transl. Res. 2020;13:894&#x2013;899. doi: 10.1007/s12265-020-10031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12265-020-10031-6</ArticleId><ArticleId IdType="pmc">PMC7250255</ArticleId><ArticleId IdType="pubmed">32458400</ArticleId></ArticleIdList></Reference><Reference><Citation>Aj&#x10d;Evi&#x107; M., Iscra K., Furlanis G., Michelutti M., Miladinovi&#x107; A., Stella A.B., Ukmar M., Cova M.A., Accardo A., Manganotti P. Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Sci. Rep. 2023;13:5808. doi: 10.1038/s41598-023-32275-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-32275-3</ArticleId><ArticleId IdType="pmc">PMC10086005</ArticleId><ArticleId IdType="pubmed">37037833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp J.A., Dressing A., Blazhenets G., Bormann T., Rau A., Schwabenland M., Thurow J., Wagner D., Waller C., Niesen W.D., et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021;144:1263&#x2013;1276. doi: 10.1093/brain/awab009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab009</ArticleId><ArticleId IdType="pmc">PMC8083602</ArticleId><ArticleId IdType="pubmed">33822001</ArticleId></ArticleIdList></Reference><Reference><Citation>Furlanis G., Stella A.B., Biaduzzini F., Bellavita G., Frezza N.A., Olivo S., Menichelli A., Lunardelli A., Aj&#x10d;evi&#x107; M., Manganotti P. Cognitive deficit in post-acute COVID-19: An opportunity for EEG evaluation? Neurol. Sci. 2023;44:1491&#x2013;1498. doi: 10.1007/s10072-023-06615-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-023-06615-0</ArticleId><ArticleId IdType="pmc">PMC9902820</ArticleId><ArticleId IdType="pubmed">36749529</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganotti P., Michelutti M., Furlanis G., Deodato M., Stella A.B. Deficient GABABergic and glutamatergic excitability in the motor cortex of patients with long-COVID and cognitive impairment. Clin. Neurophysiol. 2023;151:83&#x2013;91. doi: 10.1016/j.clinph.2023.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2023.04.010</ArticleId><ArticleId IdType="pmc">PMC10170904</ArticleId><ArticleId IdType="pubmed">37210757</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>